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Aims Pre-existing cardiovascular diseases (CVDs) have been proposed to identify patients at higher risk of adverse cor-
onavirus disease 2019 (COVID-19) outcomes, but existing evidence is conflicting. Thus, it is unclear whether pre-




In a nationwide Danish cohort of hospital-screened COVID-19 patients aged >_40, we investigated if pre-existing
CVDs predict the 30-day risk of (i) composite outcome of severe COVID-19 and (ii) all-cause mortality. We esti-
mated 30-day risks using a Cox regression model including age, sex, each CVD comorbidity, chronic obstructive
pulmonary disease-asthma, diabetes, and chronic kidney disease. To illustrate CVD comorbidities’ importance, we
evaluated the predicted risks of death and severe infection, for each sex, along ages 40–85. In total, 4090 COVID-
19 hospital-screened patients were observed as of 26 August 2020; 22.1% had >_1 CVD, 23.7% had severe infection
within 30 days and 12.6% died. Predicted risks of both outcomes at age 75 among men with single CVD comorbid-
ities did not differ in clinically meaningful amounts compared with men with no comorbidities risks for the compos-
ite outcome of severe infection; women with heart failure (28.2%; 95% CI 21.1–37.0%) or atrial fibrillation (30.0%;
95% CI: 24.2–36.9%) showed modest increases compared with women with no comorbidities (24.0%; 95% CI:
21.4–26.9%).
...................................................................................................................................................................................................
Conclusions The results showing only modest effects of CVDs on increased risks of poor COVID-19 outcomes are important
in allowing public health authorities and clinicians to provide more tailored guidance to cardiovascular patients,
who have heretofore been grouped together as high risk due to their disease status.
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Based upon preliminary data, several countries have considered peo-
ple with cardiovascular diseases (CVDs) to be a high-risk group for
severe outcomes following infection with SARS-CoV-2, the causative
agent of coronavirus disease 2019 (COVID-19).1 Many health
authorities have thus recommended stricter social distancing and/or
isolation for CVD patients as compared with the baseline popula-
tion.2 While these measures may reduce the risk of COVID-19 infec-
tion, they likely have negative consequences; for example, they
potentially contribute to poor mental and physical health during iso-
lation,3 and/or possibly a reduced likelihood of receiving treatment
for non-COVID-19-related issues.4,5 Additionally, in-hospital deci-
sions, such as triaging for intensive care unit (ICU) admission, are
informed by the perceived likelihood of surviving. Therefore, it is im-
perative that clinicians and health policymakers have an accurate
understanding of the interplay between CVD, COVID-19 infection,
and outcomes. However, the evidence concerning the link between
individual CVDs and risks of severe COVID-19 outcomes is mixed.
Several studies suggest that pre-existing CVD comorbidities are
associated with an increased risk of mortality following COVID-19 in-
fection.6–12 However, it remains unclear how COVID-19 prognosis
differs between different types of CVDs. One study using a New
York cohort shows that heart failure, but not coronary artery disease
is associated with increased risk,12 while a study with a smaller
Chinese cohort shows those with coronary heart disease were less
likely to recover.10 Additionally, a smaller case-series analysis shows
those with underlying CVD who do not develop myocardial injury
during admission are not at increased risk.8 Moreover, one cohort
study finds no independent association between CVDs and COVID-
19 mortality.13
Identifying groups most likely to have severe outcomes of
COVID-19 is critical in allowing the healthcare system to priori-
tize allocation of prevention and treatment resources where it is
most needed.14,15 This will allow more tailored guidance that can
minimize the burden of the epidemic without increasing the risk
of poor outcomes due to COVID-19 infection. Additionally, it will
be useful for improving epidemic models and projections of epi-
demic burden that are important for allocating appropriate
resources. Lastly, clinicians can use the data to better inform their
treatment and advice to patients.
Denmark has had 4090 cases among people >_40 years of age and
516 deaths within 30 days of COVID-19 diagnosis as of 26 August
2020 as registered in the National Patient Registry that includes hos-
pitalized cases as well as hospital outpatient screenings. In this study,
we described the characteristics of all COVID-19 diagnosed cases
among a primary population of hospital-screened people aged >_40
reported to the national patient databases as of 26 August 2020, and
a secondary population of all SARS-CoV-2 polymerase chain reaction
(PCR) positive cases aged >_40 in two regions in Denmark. For both
populations, we assessed the importance of pre-existing cardiovascu-
lar comorbidities as predictors of severe COVID-19 infection or
death. Two outcomes: (i) risk of a composite outcome of severe in-
fection (of severe COVID-19 diagnosis, ICU admission, respirator
use, or death) within 30 days of diagnosis and (ii) risk of all-cause
death within 30 days.
Methods
Data sources
Data for this study were sourced from several national data registries in
Denmark. All residents of Denmark are assigned a unique numeric identi-
fier that allows easy linking between the various registries. Hospital con-
tact information, including date and diagnosis came from the Danish
National Patient Registry; diagnoses were classified according to the
Danish version of the International Classification of Diseases, 10th revi-
sion (ICD-10). Polymerase chain reaction data came from the Danish
Microbiology Database. Prescription drug information came from the
Danish National Prescription Registry and contains data on the dispensing
date, strength and quantity of all prescription drugs purchased nationally.
Age, sex, and vital status (whether a person is a current resident, dead, or
has emigrated, along with the date of the event) came from the Danish
Civil Registration System. The completeness and quality of the Danish
registries have been described and validated previously.16,17 The present
study was approved by the data responsible institution Capital Region,
approval number P-2019-191. Personal data from Danish registries are
pseudonymized before being delivered for research purposes. No further
ethical approval is required for registry studies in Denmark.
Study populations and endpoints
The primary population was defined as all people >_40 years of age diag-
nosed with COVID-19 via hospital-based screenings (both inpatient and
outpatient) in Denmark (ICD-10 codes: B342, B342A, B972, B972A).
Patients tested outside a hospital setting are not included in the primary
population. A secondary population that included where the population
was defined as all people aged >_40 who had a positive PCR test for
SARS-CoV-2 from two regions in Denmark, Region Zealand and Capital
Region of Denmark. This population included those tested both inside
and outside of hospital settings.
There were two outcomes of interest. The first outcome was a com-
posite outcome of severe infection, consisting of diagnosis with severe
acute respiratory syndrome, care in the ICU, use of respirator, or death,
including both in- and out-of-hospital deaths, within 30 days of diagnosis.
The second outcome was death, both in- and out-of-hospital, within
30 days of COVID-19 diagnosis (Supplementary material online, Table
S1).
Subsets of the primary and secondary populations were made based
on diagnosis or test date. The first two subsets were defined from the pri-
mary population: a subset including only those with a COVID-19 diagno-
sis date <1 May 2020, a subset including only those with a diagnosis date
>_1 May 2020. The second set of subsets was defined from the secondary
population: a subset including only those with a SARS-CoV-2 positive
test date <1 May 2020, a subset including only those with a SARS-CoV-2
positive test date >_1 May 2020. These two time periods roughly corres-
pond to the lockdown period (<1 May), during which time COVID-19
testing was not widely used, especially for patients not considered high
risk, and the post-lockdown period (>_1 May), during which time testing
became more frequent nationwide.18
A sensitivity analysis was included on a subset of the primary popula-
tion restricted to all COVID-19 patients admitted to the hospital, defined
as a continuous hospital stay of >_12 h. The outcomes and the exposures
were the same as the main analysis. Figure 1 shows the definitions of each
population.
Definitions of exposures
The exposures of interest were pre-existing ischaemic heart disease,
heart failure, and atrial fibrillation. Exposures to control for included
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pulmonary disease (chronic obstructive pulmonary disease or asthma),
pre-existing diabetes (type I or II), and chronic kidney disease. Exposures
were defined using a combination of ICD-10 codes and history of pre-
scription medication usage (Supplementary material online, Table S2).
Cardiovascular comorbidities were included if diagnosis occurred be-
tween 1 January 2000, and the day before COVID-19 diagnosis. Patients
diagnosed with acute coronary syndrome in the 6 months preceding
COVID-19 diagnosis were excluded, as they likely represent a qualitative-
ly different patient group due to the recent, acute nature of their condi-
tion. Chronic obstructive pulmonary disease (COPD)-asthma was
defined as the receipt of drugs for obstructive airway diseases at least
twice within any 180-period after the age of 40 or diagnosis of COPD
(ICD-10: J41, J43-44). Selection of exposures of interest and exposure to
control for was based upon previous findings and clinical/policy relevance.
Specifically, regarding the exposures of interest, there were three main
considerations: (i) the three exposures used comprise conditions that are
more homogenous in terms of aetiology and presentation than, for ex-
ample, stroke patients. (ii) These comorbidities have high prevalence and
public health importance in Denmark. (iii) Power considerations limited
the number of exposures of interest that we could investigate.
Statistical analysis
Categorical and continuous variables were presented as n (%) and mean
(standard deviation), respectively. The time origin for all patients was the
date of COVID-19 diagnosis. Patients were followed until 26 August
2020 or death, whichever came first. Cox regression was used to predict
the risk of the outcomes within 30 days. Separate models were fitted for
the composite outcome of severe infection and the death-only outcome.
The fitted models were used to predict the absolute risk of each outcome
for each exposure of interest (ischaemic heart disease, heart failure, and
atrial fibrillation), while holding all other exposures negative, across ages
40–85 for both sexes.
The Cox model included patient age at COVID-19 diagnosis/PCR test
date, and interaction between sex and all exposures (ischaemic heart dis-
ease, heart failure, atrial fibrillation, COPD-asthma, and diabetes).
Patients’ age was included as a continuous variable with non-linear effects
by way of restricted cubic splines.19




A total of 4090 hospital-screened people aged >_40 were diagnosed
with COVID-19 and included in the primary population. A total of
904 (22.1%) had at least one CVD comorbidity, 541(13.2%) had is-
chaemic heart disease, 271 (6.6%) had heart failure, and 479 (11.7%)
had atrial fibrillation (Table 1). The three most frequent combinations
of comorbidities among those with at least one CVD were ischaemic
heart disease only (n = 173, 4.2%), atrial fibrillation only (n = 150,
3.7%), and ischaemic heart disease combined with diabetes (n = 45,
1.1%) (Supplementary material online, Table S3). As of 26 August
2020, a total of 969 (23.7%) had met the definition for severe infec-
tion (severe COVID-19 diagnosis, ICU admission, respirator use, or
death) within 30 days of diagnosis; of these, 191 (19.7%) had ischae-
mic heart disease, 119 (12.3%) had heart failure, and 204 (21.1%) had
atrial fibrillation. A total of 516 (12.6%) had died within 30 days of
diagnosis; of these, 115 (22.3%) had ischaemic heart disease, 90
(17.4%) had heart failure, and 150 (29.1%) had atrial fibrillation. A
total of 3021 (75.3%) had neither of the outcomes of interest after
30 days of follow-up; of these, 333 (11.0%) had ischaemic heart dis-
ease, 146 (4.8%) had heart failure, and 264 (8.7%) had atrial fibrillation
(Table 2). A total of 100 (2.4%) had neither of the outcomes of inter-
est and had <30 days of follow-up by the end of data collection.
Patients with continuous hospital stays >12 h accounted for 58.2%
(n = 2379) of the study population.
A total of 3440 patients were diagnosed before 1 May 2020 (lock-
down period), and 650 were diagnosed between 1 May and 26
August 2020 (post-lockdown). The patient characteristics of the pri-
mary population in the lockdown and post-lockdown periods are
shown in Supplementary material online, Tables S4 and S5, and the
outcomes of interests stratified by exposures of interest for the same
populations, respectively, are shown in Supplementary material on-
line, Tables S6 and S7.
A total of 5870 people had a PCR positive test for SARS-CoV-2 in
Region Zealand or Capital Region of Denmark and were included in
the secondary population. Of these, 4423 had a test date before 1
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Figure 1 Definition of primary and secondary populations and
sub-populations.






/ehjqcco/article/7/2/172/5941478 by Aalborg U


























..May and 26 August (post-lockdown). The distributions of exposures
in the entire secondary population, the lockdown, and the post-
lockdown populations are shown in Supplementary material online,
Tables S8–S10, respectively, and the distributions of the
outcomes of interests are shown in Supplementary material online,
Tables S11–S13.
Risk of severe infection and death
To illustrate the importance of the CVD comorbidities as risk factors,
Figure 2 shows the 30-day risk of the composite outcome of severe
infection (severe COVID-19 diagnosis, ICU admission, respirator
use, or death) for the entire primary population and Supplementary
material online, Figures S1 and S2 show the same outcome, but for
the lockdown and post-lockdown populations, respectively,
Supplementary material online, Figures S3–S5 show the same out-
come for the entire secondary population, the lockdown subset, and
the post-lockdown subset of the secondary populations, respectively.
Figure 3 shows the risk of 30-day mortality across all ages by sex for
single CVD comorbidities for the entire primary population, and
Supplementary material online, Figures S6 and S7 show the same out-
come for the lockdown and post-lockdown populations, respectively.
Supplementary material online, Figures S8–S10 show the same out-
come for the entire secondary population, the lockdown subset, and
the post-lockdown subset of the secondary populations, respectively.
To illustrate the importance of multiple CVD comorbidities, Figures 4
and 5 show the same outcomes (composite outcome of severe infec-
tion and death, respectively) for the entire primary population, but
for people with more than one pre-existing CVD comorbidity. We
report below the risks for a 75-year old as an example patient using
the model fitted to the entire primary population.
The predicted risk of the composite outcome of severe infection
for 75-year-old males with no comorbidities is 40.5% (95% CI: 37.3–
43.9). The corresponding risks for 75-year-old males with single
CVD comorbidities were as follows: ischaemic heart disease, 33.9%
....................................................................................................................................................................................................................









Age 63.5 (14.9) 73.4 (11.6) 76.9 (11.3) 77.6 (11.1)
Sex 2043 (50.0) 333 (61.6) 162 (59.8) 266 (55.5)
Ischaemic heart disease 541 (13.2) 470 (100.0) 151 (55.7) 163 (34.0)
Heart failure 271 (6.6) 151 (27.9) 236 (100.0) 149 (31.1)
Atrial fibrillation 479 (11.7) 163 (30.1) 149 (55.0) 401 (100.0)
COPDa 627 (15.3) 143 (26.4) 99 (36.5) 131 (27.3)
Diabetes 598 (14.6) 169 (31.2) 100 (36.9) 121 (25.3)
Chronic kidney disease 293 (7.2) 102 (18.9) 77 (28.4) 86 (18.0)
Cancer 423 (10.3) 73 (13.5) 43 (15.9) 83 (17.3)
Hypertension 1281 (31.3) 369 (68.2) 233 (86.0) 324 (67.6)
Stroke 389 (9.5) 100 (18.5) 64 (23.6) 116 (24.2)
Liver disease 111 (2.7) 15 (2.8) 9 (3.3) 10 (2.1)
Beta-blockers 641 (15.7) 261 (48.2) 180 (66.4) 264 (55.1)
Calcium channel Blockers 571 (14.0) 123 (22.7) 32 (11.8) 87 (18.2)
Ras inhibitor 1029 (25.2) 251 (46.4) 147 (54.2) 179 (37.4)
Loop diuretics 486 (11.9) 182 (33.6) 166 (61.3) 189 (39.5)
Asprin 401 (9.8) 208 (38.4) 72 (26.6) 43 (9.0)
Statin 942 (23.0) 316 (58.4) 133 (49.1) 190 (39.7)
Anticoagulation 446 (10.9) 146 (27.0) 137 (50.6) 328 (68.5)
aCOPD, chronic obstructive pulmonary disease.
....................................................................................................................................................................................................................
Table 2 Outcomes of interest stratified by exposures of interest in primary population
Exposure of interest Death within
30 days (n 5 516)
Composite outcome of severe
infection within 30 days (n 5 972)a
Non-severe outcome
within 30 days (n 5 3018)b
Atrial fibrillation 150 (29.1) 204 (21.0) 264 (8.7)
Heart failure 90 (17.4) 119 (12.2) 146 (4.8)
Ischaemic heart disease 115 (22.3) 192 (19.8) 332 (11.0)
aDefined as diagnosis with severe acute respiratory syndrome, care in the ICU, use of respirator, or death, within 30 days of diagnosis.
bDefined as people who had 30 days of follow-up with no outcome of interest.
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..(95% CI: 28.5–40.1%); heart failure, 43.4% (95% CI: 34.8–53.1%); and
atrial fibrillation, 39.4% (95% CI: 33.5–45.9%). For multiple CVD
comorbidities, the corresponding risks for 75-year males were as fol-
lows: ischaemic heart disease and heart failure, 36.5% (95% CI: 28.4–
46.0%); ischaemic heart disease and atrial fibrillation, 32.9% (95% CI:
26.6–40.3%); heart failure and atrial fibrillation, 42.2% (95% CI: 33.9–
51.7%); and ischaemic heart disease, heart failure, and atrial fibrilla-
tion, 35.5% (95% CI: 28.0–44.2%).
The predicted risk of the composite outcome of severe infection
for 75-year-old females with no comorbidities is 24.0% (95% CI:
21.4–26.9%). The corresponding risk for 75-year-old females with
single CVD comorbidities were as follows: ischaemic heart disease,
22.6% (95% CI: 17.3–29.1%); heart failure, 28.2% (95% CI: 21.1–
37.0%); and atrial fibrillation, 30.0% (95% CI: 24.2–37.0%). For mul-
tiple CVD comorbidities, the corresponding risks for 75-year females
were as follows: ischaemic heart disease and heart failure, 26.6%
(95% CI: 18.9–36.6%); ischaemic heart disease and atrial fibrillation,
28.3% (95% CI: 21.5–36.7%); heart failure and atrial fibrillation 35.0%
(95% CI: 26.6–45.1%); and ischaemic heart disease, heart failure and
atrial fibrillation, 33.1% (95% CI: 24.9–43.2%).
The predicted risk of death for 75-year-old males with no comor-
bidities is 22.3% (95% CI: 19.4–25.5%). The corresponding risks for
75-year-old males with single CVD comorbidities were as follows: is-
chaemic heart disease, 15.5% (95% CI: 12.1–19.8%); heart failure,
27.6% (20.5–36. 5%); and atrial fibrillation, 23.7% (19.0–29.3%). For
multiple CVD comorbidities, the corresponding risks for 75-year
males were as follows: ischaemic heart disease and heart failure,
19.4% (95% CI: 13.9–26.7%); ischaemic heart disease and atrial fibril-
lation, 16.5% (95% CI: 12.3–22.1%); heart failure and atrial fibrillation
29.3% (95% CI: 22.2–38.0%); and ischaemic heart disease, heart fail-
ure, and atrial fibrillation, 20.7% (95% CI: 15.2–27.7%).
The predicted risk of death for 75-year-old females with no
comorbidities is 12.8% (95% CI: 10.8–15.2%). The corresponding
risks for 75-year-old females with single CVD comorbidities were as
follows: ischaemic heart disease, 10.1% (95% CI: 7.0–14.2%); heart
failure, 19.1% (13.4–26.7%); and atrial fibrillation, 18.1% (13.8–
23.4%). For multiple CVD comorbidities, the corresponding risks for
75-year males were as follows: ischaemic heart disease and heart fail-
ure, 15.1% (95% CI: 9.9–22.6%); ischaemic heart disease and atrial fib-
rillation, 14.3% (95% CI: 9.9–20.3%); heart failure and atrial fibrillation
26.5% (95% CI: 19.1–35.9%); and ischaemic heart disease, heart fail-
ure, and atrial fibrillation, 21.1% (95% CI: 14.8–29.5%).
The predicted risks of the composite outcome of severe infection
across all combinations of included risk factors for a 75-year-old male
and female can be found in Supplementary material online, Figures
S11 and S12, respectively, and the corresponding predicted risks of
death for a 75-year-old male and female can be found in
Supplementary material online, Figures S13 and S14.
Female Male






































































































































Figure 2 Predicted 30-day risk of the composite outcome of severe infection (severe COVID-19 diagnosis, intensive care unit admission, respir-
ator use, or death) among hospital-screen patients (primary population). Predictions are made based across ages for both sexes for each cardiovascu-
lar comorbidity in the absence of any other comorbidities.
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..A sensitivity analysis performed using only hospital admitted
patients from the primary population (n = 2380) showed similar
results of predicted risks of death or severe infection (Supplementary
material online, Figures S15 and S16).
Discussion
We examined if pre-existing ischaemic heart disease, heart failure, or
atrial fibrillation were predictors of worse infection among hospital-
screened COVID-19 patients. The major novel findings in this study
include establishing that, among men with single CVD comorbidities,
neither ischaemic heart disease, heart failure, nor atrial fibrillation
predicted a higher risk of severe COVID-19 outcomes as compared
with baseline risk of someone with no comorbidities, while among
women, heart failure and atrial fibrillation each modestly increased
risk. However, when restricting the analysis to the period during
which COVID-19 testing was widely available (the post-lockdown
period), the increased risk among women with heart failure or atrial
fibrillation disappeared. The same trends appeared in the analyses of
both the primary (hospital diagnosed) and the secondary (PCR posi-
tive) populations. Additionally, while women who have both heart
failure and atrial fibrillation had a substantially higher predicted risk of
death or severe infection when including the entire primary
population, when restricting the data to the post-lockdown this
increased risk also disappeared.
Our study adds important nuances to previous findings that pre-
existing CVDs are risk factors for poor COVID-19 outcomes.8–12
While others have reported on the increased risk due to heart fail-
ure,12 previous investigations of atrial fibrillation included cohorts
with too few patients with the comorbidity to meaningfully assess the
importance on COVID-19 outcomes.10 Additionally, we showed for
the first time that sex may play a role in determining the effect that
pre-existing CVDs have on the risk of poor COVID-19 outcomes.
While we found that men in general had a higher risk of severe in-
fection and death, pre-existing CVD seemed to predict a higher risk
of poor COVID-19 outcomes only in women. However, the role of
sex changed when restricting the analysis to the post-lockdown
population, where heart failure showed a protective effect on risk of
poor COVID-19 outcomes. The reason for this sex discrepancy is
unknown, though female sex has been linked to lower Angiotensin-
converting enzyme-2 receptor expression, which has been proposed
to play a role in COVID-19 and cardiac disease.21 Our findings are
speculative, however, and further studies are needed to explore
whether the sex differences arise from biological mechanisms or
from the way in which our study population was selected.
Although we found that several CVD comorbidities are not linked
with worse COVID-19 outcomes, especially among men, our data
Female Male



















































































Figure 3 Predicted 30-day risk of death among hospital-screen patients (primary population). Predictions are made across ages for both sexes for
each cardiovascular comorbidity in the absence of any other comorbidities.
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..supported previous findings indicating a higher overall comorbidity
burden coincides in a higher risk of worse outcomes. 22 It is thus pos-
sible that CVD comorbidities not associated with clinically significant
increases in risk of poor COVID-19 outcomes in our study still pre-
sent a real increase in risk; the effect size, however, may be too small
to be illuminated by our sample. Additionally, patients with multiple
pre-existing CVD comorbidities, including comorbidities not investi-
gated in our study, likely represent a higher risk of poor outcomes.
This would be consistent with previous work showing that pre-
existing CVD comorbidities impact both the clinical course and out-
comes of CVD patients.23
Our results support the utility of more granular COVID-19 rec-
ommendations for CVD patients. Given the potential longevity of the
pandemic, it is imperative for the mental and physical well-being of
CVD patients that restrictions on social and physical activity are as
minimal as necessary. Tailoring recommendations for CVD patients
not at higher risk from COVID-19 infections would be an important
dimension for improving quality of life and reducing collateral damage
for these patients. However, although our findings suggest that is-
chaemic heart disease, heart failure, or atrial fibrillation are not im-
portant predictors of severe outcomes of COVID-19, especially
among men, many patients with these highly prevalent cardiovascular
comorbidities will be at increased risk of severe COVID-19 due to
age alone.
Strength and limitations
A major strength of the present study was our access to complete
medical histories of all hospital-screened COVID-19 patients. This
allowed us to investigate the importance of pre-existing CVD comor-
bidities on the absolute risk of severe COVID-19 outcomes in a na-
tionwide cohort of hospital-screened COVID-19 patients in a public
healthcare system controlling for age, sex, and other comorbidities
with multivariate analysis. Additionally, we expect to receive monthly
data updates from the Danish health authorities.
There were, however, some data limitations to our study. The
study population during the lockdown period was likely a highly
selected population, as testing rates were low, test-positivity rates
high. Additionally, the primary population only included those who
have had contact with the Danish hospital system (both inpatient and
outpatient contacts). This suggests our estimates of absolute risk
were likely biased upwards during the lockdown period and thus like-
ly represent more severe cases as compared with the entirety of the
true SARS-CoV-2 positive population. Moreover, if COVID-19
patients who had no CVD history had less severe infections, and
were less likely to be in contact with the hospital system and enter
our primary population, our estimates of the effect of CVD diseases
would be biased towards the null. Conversely, there is evidence of a
reduction in healthcare-seeking behaviour during the pandemic
among those with a history of CVD, or those experiencing CVD-
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Figure 4 Predicted 30-day risk of the composite outcome of severe infection (severe COVID-19 diagnosis, intensive care unit admission, respir-
ator use, or death) among hospital-screen patients (primary population). Predictions are made across ages for both sexes for each combination of
cardiovascular comorbidities in the absence of any other comorbidities.
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related symptoms.24–29 If those with pre-existing CVD comorbidities
were more likely to avoid contact with the hospital system than their
CVD-free peers, unless their condition deteriorated to the point
requiring intervention, then our estimates would be biased in the op-
posite direction, away from the null. Indeed, the analysis using only
the post-lockdown data from both the primary (hospital contacts)
and secondary populations (PCR positive cases from Region Zealand
and Capital Region of Denmark) suggests data from during the lock-
down period was biased away from the null. Taken together, this sug-
gests our conclusions of minimal increases in absolute risk due to
pre-existing CVD comorbidities were robust.
Our dataset was likely missing ICU admission data for those
patients who were not yet discharged from hospital as of 26 August
2020, and 2.4% of the primary study population had not yet reached
an endpoint, either 30-day event free, severe infection, or death, by
the date of our data capture. Another data limitation arose from lack
of data concerning potential confounding variables, such as body
mass index. Previous work has demonstrated that individuals with
obesity had higher odds of poor COVID-19 outcomes.30 The inter-
actions between CVD comorbidities, obesity, and COVID-19 out-
comes deserve further investigation. Yet despite these limitations,
our analysis allowed us to bracket the potential effect size of the
increased absolute risk of severe outcomes predicted by pre-existing
CVD status.
Finally, the generalizability of our findings may present another
limitation. The epidemiology of the COVID-19 outbreak varies
across countries, as different countries employed different manage-
ment and control approaches, which may affect the apparent impact
of CVD comorbidities. The Danish authorities enacted strict lock-
downs earlier in the epidemic as compared with some countries
where the epidemic was seeded earlier in the calendar year. The
resulting epidemic peak in Denmark, and the corresponding peak
burden on the healthcare system, was lower than many countries
and regions.18 In some regions where healthcare systems were more
stressed, and/or the ICU capacity exceeded during the epidemic
peak, patients with pre-existing comorbidities may have received sub-
standard care These patient groups in these regions may have thus
been at higher risk of poor outcomes, independent of any causal rela-
tionship between CVD comorbidities and SARS-CoV-2 infec-
tion.31,32 In contrast, Danish ICU capacity was not exceeded during
the study period.33 Additionally, Denmark has an advanced health-
care system with universal healthcare for all residents and a high qual-
ity of cardiac care.34 Thus, patients in the present study with stable
CVD may have represented a relatively well-treated population. Our
Female Male

























Heart Disease and  
Heart  
Failure
Ischemic Heart Disease and Heart Failure
Female Male

























Heart Disease and Atrial  
Fibrillation
Ischemic Heart Disease and Atrial Fibrillation
Female Male

























Failure and Atrial  
Fibrillation
Heart Failure and Atrial Fibrillation
Female Male

























Heart Disease,  
Heart  
Failure and Atrial  
Fibrillation
Ischemic Heart Disease, Heart Failure and Atrial Fibrillation
Figure 5 Predicted 30-day risk of death among hospital-screen patients (primary population). Predictions are made across ages for both sexes for
each combination of cardiovascular comorbidities in the absence of any other comorbidities.
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findings may not be generalizable to countries with poorer cardiac
care or instances where healthcare systems are overburdened by the
COVID-19 epidemic.
Conclusion
Pre-existing ischaemic heart disease, heart failure, or atrial fibrillation
in a population of hospital-screened COVID-19 patients were not
important predictors for risk of severe infection among men, while
heart failure and atrial fibrillation were both potentially a predictor of
modest increased risk of poor outcomes among women, but only
early in the epidemic when COVID-19 testing rates were low. Our
findings show the need for more bespoke public health and clinical
recommendations concerning cardiovascular patients.
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